《新股情報》銀諾醫藥孖展增至3096億元超逾4552倍今年排第三 X
12/08/2025 10:48
<匯港通訊>  針對糖尿病和其他代謝性疾病的候選藥物管業務的廣州銀諾醫藥-B(02591)將於今日中午截止公開發售,惟券商續接受銀諾醫藥孖展認購,令借出孖展額增至3096億港元,相當於集資6829萬港元計,超額認購逾4552倍,已超越昨日掛牌的中慧生物-B(02627)超購逾4006倍,成為今年超購第三位新股,最終或有力挑戰於今年3月3日掛牌超購第二位的蜜雪集團(02097),蜜雪當時超購逾5257倍。(BC)

#銀諾醫藥  #IPO  

(C) Copyright by Infocast Ltd. All Rights Reserved.

Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.